WO2002000853A3 - Regulation de la protease de type caspase 1 humaine - Google Patents

Regulation de la protease de type caspase 1 humaine Download PDF

Info

Publication number
WO2002000853A3
WO2002000853A3 PCT/EP2001/007287 EP0107287W WO0200853A3 WO 2002000853 A3 WO2002000853 A3 WO 2002000853A3 EP 0107287 W EP0107287 W EP 0107287W WO 0200853 A3 WO0200853 A3 WO 0200853A3
Authority
WO
WIPO (PCT)
Prior art keywords
protease
human caspase
regulation
reagents
caspase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/007287
Other languages
English (en)
Other versions
WO2002000853A2 (fr
Inventor
Shyam Ramakrishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to US10/311,954 priority Critical patent/US20040132023A1/en
Priority to EP01947406A priority patent/EP1297154A2/fr
Priority to AU2001269095A priority patent/AU2001269095A1/en
Publication of WO2002000853A2 publication Critical patent/WO2002000853A2/fr
Publication of WO2002000853A3 publication Critical patent/WO2002000853A3/fr
Anticipated expiration legal-status Critical
Priority to US11/357,125 priority patent/US7192732B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22036—Caspase-1 (3.4.22.36), i.e. interleukin-1-beta-convertase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des réactifs qui régulent l'activité de la protéase de type caspase 1 humaine et des réactifs qui se lient à des produits géniques de la protéase de type caspase 1 humaine. Ces réactifs peuvent être utilisés pour traiter une maladie allergique, l'asthme, le cancer et les maladies neurodégénératives.
PCT/EP2001/007287 2000-06-26 2001-06-26 Regulation de la protease de type caspase 1 humaine Ceased WO2002000853A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/311,954 US20040132023A1 (en) 2000-06-26 2001-06-26 Regulation of human caspase-1-like protease
EP01947406A EP1297154A2 (fr) 2000-06-26 2001-06-26 Regulation de la protease de type caspase 1 humaine
AU2001269095A AU2001269095A1 (en) 2000-06-26 2001-06-26 Regulation of human caspase-1-like protease
US11/357,125 US7192732B2 (en) 2000-06-26 2006-02-21 Regulation of human caspase-1-like protease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21400900P 2000-06-26 2000-06-26
US60/214,009 2000-06-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10311954 A-371-Of-International 2001-06-26
US11/357,125 Continuation US7192732B2 (en) 2000-06-26 2006-02-21 Regulation of human caspase-1-like protease

Publications (2)

Publication Number Publication Date
WO2002000853A2 WO2002000853A2 (fr) 2002-01-03
WO2002000853A3 true WO2002000853A3 (fr) 2002-08-08

Family

ID=22797417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007287 Ceased WO2002000853A2 (fr) 2000-06-26 2001-06-26 Regulation de la protease de type caspase 1 humaine

Country Status (4)

Country Link
US (2) US20040132023A1 (fr)
EP (1) EP1297154A2 (fr)
AU (1) AU2001269095A1 (fr)
WO (1) WO2002000853A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746167A1 (fr) * 2005-07-20 2007-01-24 Apoxis SA Méthode d'identification des components anti-inflammatoires.
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
DE102011118024A1 (de) * 2011-08-01 2013-02-07 Technische Universität Dresden Inhibitor der Expression der Pro-Caspase 1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858778A (en) * 1996-12-27 1999-01-12 Thomas Jefferson University SF caspase-1 and compositions for making and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962301A (en) 1992-06-12 1999-10-05 Massachusetts Institute Of Technology Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
WO1994006906A1 (fr) 1992-09-18 1994-03-31 Merck & Co., Inc. ADN CODANT L'ENZYME DE CONVERSION DE L'INTERLEUKINE 1β PRECURSEUR MURIN
US5654146A (en) * 1995-05-31 1997-08-05 Incyte Pharmaceuticals, Inc. Human ice homolog
US5869315A (en) * 1995-12-18 1999-02-09 Basf Aktiengesellschaft Modified interleukin-1β converting enzyme with increased stability
CA2328457A1 (fr) * 1998-06-20 1999-12-29 Washington University Complexes peptidiques de permeation membranaire destines a l'imagerie medicale, au diagnostic et a la therapie pharmaceutique
EP1292684A2 (fr) * 2000-06-16 2003-03-19 Incyte Genomics, Inc. Proteases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858778A (en) * 1996-12-27 1999-01-12 Thomas Jefferson University SF caspase-1 and compositions for making and methods of using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 10 October 1998 (1998-10-10), ROBERT STRAUSBERG: "similar to gb:M87507 INTERLEUKIN-1 BETA CONVERTASE PRECURSOR (HUMAN)", XP002192390, retrieved from EBI Database accession no. AI189378 *
DATABASE EMBL [online] 28 October 1998 (1998-10-28), ROBERT STRAUSBERG: "similar to gb:M87507 INTERLEUKIN-1 BETA CONVERTASE", XP002192391, retrieved from EBI Database accession no. AI220630 *
DATABASE SWALL [online] 1 April 1993 (1993-04-01), THORNBERRY,N.A., ET AL.: "INTERLEUKIN-1 BETA CONVERTASE (IL-1BC) (EC 3.4.22.36)", XP002192392, retrieved from EBI Database accession no. P29466 *
See also references of EP1297154A2 *

Also Published As

Publication number Publication date
WO2002000853A2 (fr) 2002-01-03
US20060141552A1 (en) 2006-06-29
US20040132023A1 (en) 2004-07-08
EP1297154A2 (fr) 2003-04-02
US7192732B2 (en) 2007-03-20
AU2001269095A1 (en) 2002-01-08

Similar Documents

Publication Publication Date Title
WO2003099771A3 (fr) Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2005078124A3 (fr) Marqueur diagnostique pour le cancer
WO2001030381A3 (fr) Utilisation d'inhibiteurs csf-1
WO2006092668A3 (fr) Compositions proteiques de cellules cutanees foetales pour le traitement d'affections, de troubles ou de maladies cutanes et procedes de fabrication et d'utilisation de celles-ci
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
WO2005097119A3 (fr) Inhibiteurs de pten
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
WO2002036783A3 (fr) Regulation de l'histone deacetylase chez l'homme
WO2004056768A3 (fr) Utilisation de 2,5-diamidoindoles substitues pour le traitement de maladies urologiques
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
WO2003026566A3 (fr) Atlastine
ATE356208T1 (de) Regulation des menschliches lipoxin a4 rezeptor- ähnliches protein
AU2001292310A1 (en) Method of regulating the activity of expression product of gene transferred intoliving body
AU2002353031A1 (en) Use of parapox b2l protein to treat cancer and modify immune responses
AU2002364757A1 (en) Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases
WO2002081705A3 (fr) Regulation de la proteine humaine de type acetyltransferase gnat
WO2002000891A3 (fr) Regulation de la protease aspartyle humaine de type napsin
WO2002062974A3 (fr) Regulation de la proteine humaine elongase hselo1
WO2001090160A3 (fr) Regulation de la serine/threonine kinase humaine analogue a p78
WO2003099863A3 (fr) Proteines de liaison a la resistine, elaboration et utilisation correspondantes
WO2002052016A3 (fr) Regulation d'enzyme de type proteine l-isoaspartate o-methyltransferase humaine
AU2002330713A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
WO2002034920A3 (fr) Regulation de la proteine de type ceruloplasmine humaine
WO2002062975A3 (fr) Regulation de la proteine humaine du type elongase hselo1
WO2002051996A3 (fr) Regulation de proteine humaine du type cyclophiline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001947406

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10311954

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001947406

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP